Why the study?
Does short-term treatment with ularitide improve clinical outcomes or reduce long-term cardiovascular mortality in patients with acute heart failure?
Does short-term treatment with ularitide improve clinical outcomes or reduce long-term cardiovascular mortality in patients with acute heart failure?
Short-term treatment with ularitide in acute heart failure provides favorable physiological effects but fails to improve clinical composite endpoints or long-term cardiovascular mortality.
Answers are grounded in this paper and cite their sources.
Caution against ularitide use in acute HF despite hemodynamic effects; challenges surrogate-driven expectations for natriuretic peptides.
In patients with acute heart failure, ularitide exerted favorable physiological effects (without affecting cardiac troponin levels), but short-term treatment did not affect a clinical composite end point or reduce long-term cardiovascular mortality. (Funded by Cardiorentis; TRUE-AHF ClinicalTrials.gov number, NCT01661634 .).
No takes yet. Share an insight, caveat, or question.
Packer et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: